TrialThe Journal of antimicrobial chemotherapy2019

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

Kristen Andreatta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.